Longevity Medicine Decades: Past and Future

What the last ten years built, what the next ten will test.

On 9 June 2026 the first patient was treated with a therapy created to make their cells biologically younger.

It was one of the first human tests of a theory at the core of longevity science: that ageing is partly information the body has forgotten, and that our cells can be taught to rewrite it.

While this test made headlines, it also made serious scientists nervous. A leading neurobiologist told Nature the treatment had attracted a lot of hype, and that if it went catastrophically wrong it could set the whole field back.

This sentiment is significant. A clean result would be the strongest proof yet that ageing can be slowed, or even for a time, reversed. However, a poor outcome would not just end the trial. The field fears a repeat of Jesse Gelsinger, the teenager whose death in a 1999 gene-therapy trial froze that field for years.

A reprogramming disaster could drain the hard-earned funding, trust and momentum that longevity science has only just gathered. So stakes are high, remaining so with each early trial run in full public view.

The TL;DR? Stakes are high because the impact of longevity medicine can be era-defining. 

• Ageing is no longer a vague decline. It is a set of measurable, modifiable mechanisms.
• And the first treatments aimed at them have reached actual patients.

So longevity has arrived? Not quite. The science is real and the wins are genuine, but the risk remains that hype runs ahead of evidence. 

• Epigenetic clocks can read biological age, though not yet reliably enough for a single patient or a regulator.
• GLP-1 drugs cut serious disease in large trials, but have not been shown to slow ageing itself.
• A reprogramming therapy is being tested in a human eye, the boldest step so far and the least proven.

Read on for what the last ten years built, what the next ten will test, and what it means for clinicians, investors and anyone who takes an interest in ageing better.

Foundations for optimism

This new trial rests on a quieter decade of progress. In that time the field learned to measure ageing, to target it, to move the first treatments toward patients, and, just as importantly, to discard what did not work.

Measurement came first. Biological age is an old idea, but for a long time there was no way to read it. In 2013, Steve Horvath built the first epigenetic clock, estimating age across tissues to within about three years.

Second-generation clocks sharpened the picture, with models like GrimAge predicting disease and mortality more directly. Measurement also began to reveal that ageing may not move at a steady pace. A 2024 Stanford study found that molecular changes cluster around the ages of 44 and 60, which hints that when you intervene may matter as much as how.

Once ageing could be measured, it could be targeted. Researchers organised it into a set of hallmarks, each one a possible point of intervention. Senescent cells, the worn-out cells that linger and cause damage, were the first validated target: clearing them in mice improved health across multiple organs, and that breadth was enough to justify senolytics as a drug class.

Other hallmarks followed, among them chronic inflammation, NAD+ decline, mitochondrial dysfunction, failing autophagy and disrupted nutrient sensing. The emerging view is that no single drug will be enough, and attention is shifting toward combinations, much as it did in cancer and HIV care. Early work supports the idea: rapamycin plus acarbose outperformed either drug alone. It may be the field's most important and least tested idea.

Targeting is one thing, but translation is where most therapies fail. The path from laboratory to clinic takes 10 to 15 years, and roughly nine in ten candidates fail. The first longevity therapies are only now emerging from that pipeline. GLP-1 drugs are already in wide use, and a 2026 trial suggests semaglutide slows epigenetic clocks.

Rapamycin is in human trials at low, intermittent doses. And at the frontier sits the June reprogramming trial, the first to move from cells into a living eye. Breakthroughs like these generate headlines, and headlines are where a field's credibility is most easily lost.

The real test of a field is not only what it promises, but what it is willing to retract. Telomeres, once treated as a master switch for ageing, were cut down to a modest marker. The heritability of lifespan, long thought substantial, was revised down to 20 to 30 percent, most likely inflated by the tendency of similar people to marry.

Even popular stories have not survived scrutiny: the Blue Zones, those regions famed for exceptional lifespans, were dismantled by Saul Newman, who traced the claims to poor record-keeping and fraud, work that won an Ig Nobel Prize. A field willing to overturn its own beliefs is behaving the way a science should.

The Case for Caution

Optimism needs tempering, for three main reasons: relating to the currently narrow foundations of the field, stronger evidence for treating disease rather than slowing ageing, and implications for the clinic

Much of longevity medicine depends on measuring ageing using epigenetic clocks. These clocks perform well across large populations, where they track disease risk and mortality with reasonable accuracy.

But they were designed for groups, not individuals, and at the single-patient level they remain inconsistent. Steve Horvath, who developed the first clock, has noted that the same sample sent to different validated labs can return different biological ages. That creates a practical problem. A clinic treats one patient at a time, and a trial needs a measurement precise enough to show whether a therapy worked. No current measure of ageing meets that standard. 

The therapies raise a different kind of concern, and the ER-100 reprogramming trial shows why. A cell's age and its identity are both stored in the epigenome, the chemical marks that switch genes on and off. Reprogramming pushes those marks back toward a younger state.

Done carefully, an old cell begins to behave like a young one. Pushed too far, the cell loses its identity, drifting toward a blank, stem-cell-like state, and cells in that state can become cancerous. The risk is not confined to the target cell. A dose set for one cell type can push neighbouring cells beyond that safe range, and the mechanism is not yet fully understood.

The trial is designed to contain that risk. It excludes c-Myc, the Yamanaka factor most closely linked to cancer. It activates the genes only while the patient takes an antibiotic, for eight weeks. And it treats one eye only, allowing direct observation while the other eye remains untreated. Each safeguard carries a trade-off. c-Myc also supports cell division, so leaving it out may weaken the effect. Holding the therapy in the narrow band between safe and effective is what the trial is really testing.

The proof for treating disease is real. In the SELECT trial, 17,604 overweight adults with heart disease took semaglutide, and over about three years their risk of heart attack, stroke or cardiovascular death fell by 20 percent. That is a strong result, of a kind most treatments never reach, and other GLP-1 drugs show similar gains for heart, kidney and liver disease.

But none of this proves the drugs slow ageing. Those trials were run in people who already had heart disease, and they measured heart attacks and strokes, not ageing. The trial built to test ageing directly, TAME, which would give metformin to healthy older adults and track age-related disease as a whole, has spent nearly a decade stalled for funding, precisely because a cheap generic drug offers no company a return. 

The study suggesting semaglutide slows the epigenetic clock was small, was not its main purpose, and was run in people with HIV, with biological age only a secondary measurement. 

The honest summary is strong proof for treating disease, early hints for slowing ageing, and a wide gap between the two. 

The last concern relates to the clinic. Longevity medicine will not arrive as a single drug, but as a growing list of therapies, tests, biomarkers and protocols, each one added on top of care that is already complicated, and often with no agreed guideline to follow.

It could also fundamentally change the role of the doctor and the clinic. Most medicine treats a problem until it is fixed. A longevity patient wants something with no clear end point, to prevent illness and age well, managed over years rather than settled in one visit.

Longevity medicine asks more of clinicians on two fronts, and both are already stretched. The first is time. In 2024, doctors worked a 57.8-hour week, 13 hours of it on documentation rather than patients, and longevity care, followed over years and adjusted constantly, only adds to that load. The second is knowledge. Most working clinicians were never taught to read an epigenetic clock or judge a senolytic, so the field is asking them to deliver care it has barely started to teach. 

The decade rewards readiness

Longevity has reached a tipping point. Work is moving from the theoretical into human trials, and the promise of the field starts to gather attention, momentum and excitement.

That excitement is the field's greatest strength, and quietly its greatest risk. It draws the interest, the funding and the talent that the next decade depends on. It also breeds hype, and it makes every failure heavier, because more is now watching and more is now riding on each result.

The measurement problem is being standardised. The same epigenetic clocks that cannot yet give two labs the same answer are the focus of a coordinated effort to validate and benchmark them, the step that turns a research signal into a tool a clinic and a regulator can trust.

The evidence problem is being tested directly. Trials are now built to measure ageing itself rather than infer it, the TAME trial designed to have a regulator recognise ageing as something a drug can treat, and others testing whether today's drugs slow it in people who are not yet ill. The endpoints the field argued over for a decade are being settled.

The clinic problem is solvable. Training is arriving, with longevity medicine taught as its own discipline through institutions like the Geneva College of Longevity Science, while AI shows potential to assist with the clerical load.

Longevity medicine carries real science and loud hype side by side, and from the outside the two are hard to tell apart. Drawing that line falls to the people inside the field, and trust depends on them doing it in the open, backing what holds up and calling out what does not. A field that polices its own claims keeps the trust that a single bad headline could otherwise destroy.

The rules are not written yet. The protocols, the safety thresholds, the line between evidence and hype, are being created right now, by those running trials, building clinics and weighing the risks. Whoever helps write them will shape the decade.

That holds whether you treat patients, fund companies - or just want to age well yourself. 
The next era of medicine will be created by the people who come together, in the same room, to pool talent, vision, energy and learning for a better global future. 

That is what Next Generation Medicine 2026 is for.

7 to 10 November. Atlantis The Royal, Dubai.